ArticleCancer medicine2026
Co-Mutation of ASXL1 and KRAS Defines a Novel Ultra-Adverse-Risk Subtype of Acute Myeloid Leukemia in a Large-Scale Cohort.
Yijing Zhao, Ting Zhao, Feifei Tang, Xiaodong Mo, Yingjun Chang, Xiaosu Zhao, Lanping Xu, Yu Wang, Xiaohui Zhang, Hao Jiang and 3 more
Abstract read
In one paragraphArticle in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Yijing ZhaoPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Ting ZhaoPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Feifei TangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.ORCID https://orcid.org/0000-0003-0460-9887 Xiaodong MoPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Yingjun ChangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.ORCID https://orcid.org/0000-0002-6124-6050 Xiaosu ZhaoPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.ORCID https://orcid.org/0000-0001-7749-8087 Lanping XuPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Xiaohui ZhangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Hao JiangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Qian JiangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.ORCID https://orcid.org/0000-0001-7131-0522 Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Yuqian SunPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.ORCID https://orcid.org/0000-0003-1856-2231 Funding
Beijing Nova Program Interdisciplinary Cooperation Project 0107050Beijing Nova Program of Science and Technology Z211100002121058National Natural Science Foundation of China 82100168Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation, and "the Fundamental Research Funds for the Central Universities" BMU2021PYB005Peking University People's Hospital Research and Development Funds RDY2020-29Peking University People's Hospital Research and Development Funds RS2020-03
6 · The paper itselfAbstract
backgroundASXL1 mutation acute myeloid leukemia represents a clinically aggressive subtype with heterogeneous outcomes. Current evidence remains inconclusive regarding the prognostic relevance of the KRAS mutation partner in AML with ASXL1 mutation. The comprehensive mutational landscape and prognostic implications of co-occurring driver mutations remain poorly characterized.
methodsA total of 2788 consecutive AML patient records were reviewed. A comprehensive clinicogenomic analysis was conducted on 451 AML patients with ASXL1 or KRAS mutations from the discovery cohort (n = 394) and the independent validation cohort (n = 57) to assess the correlation between molecular profiles and clinical outcomes.
resultsThe KRAS mutation was observed in 22 (9.9%) AML cases with the ASXL1 mutation. Notably, survival analysis revealed that the ASXL1
conclusionsThese results demonstrate the independent prognostic value of ASXL1
Indexed as
Leukemia, Myeloid, AcuteMutationProto-Oncogene Proteins p21(ras)Repressor ProteinsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisYoung AdultASXL1 protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)Repressor Proteinsacute myeloid leukemiaASXL1 mutationsKRAS mutationsprognosisrelapse
Identifiers
PMID41814508
PMCPMC13093774
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390